Centre Hospitalier General — Clinical Trial Site

16 Registered trials

8 Currently recruiting

Organisation

Centre Hospitalier General

Location

Gonesse, France

Identifier

ORG-100043967

Address

2 Boulevard Du 19 Mars 1962, 95500, France

Departments

#1212: Neurology
1005:Neurologie
7005:Neurology
Multi-purpose intensive care
Neurologie
Neurology
Réanimation polyvalente
Service de Neurologie
Service de Réanimation Polyvalente

Clinical trials at this site (16)

Search interface

“Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicen… Pending

2024-520414-21-00 Adult patients with a LVOS with large core within 9 hou 5
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
KISS Evaluation of early administration of Levetiracetam in the prevention and treatment of delirium during septic shock: a randomized, doub… Recruiting

2023-510449-51-00 Adult ICU patients with septic shock 5 2025-07-31
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting

2024-513475-41-00 Multiple Sclerosis 5 2025-02-03
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment… Recruiting

2023-505420-62-00 Multiple sclerosis 5 2023-11-09
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lacta… Recruiting

2024-511866-36-00 patients hospitalized in ICU with ESBL-producing Entero 5 2023-03-11
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended

2022-501027-25-01 Multiple Sclerosis 11 2023-06-01
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 relapsing multiple sclerosis (RMS) 5 2021-07-23
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Multiple sclerosis (MS) 5 2018-07-25